Tetrahydrocannabinol in a method of treating glaucoma
Patent 4189491 Issued on February 19, 1980. Estimated Expiration Date: 
February 19, 1997. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 19, 1997. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3668224 3728360 3734930 3799946 3920809 Tri-cyclic compounds derived from thiaphloroglucinol ethers Patent #: 4025536 InventorsApplicationNo. 05/751079 filed on 12/16/1976US Classes:514/397, Additional hetero ring514/913GlaucomaExaminersPrimary: Robinson, Douglas W.Attorney, Agent or FirmInternational ClassA61K 31/35 (20060101)AbstractSignificant success in alleviating the symptoms of glaucoma is achieved by orally administering to a glaucoma sufferer a therapeutically effective, but sub-psychotropic dose of tetrahydrocannabinol (THC), which is the most active ingredient in marijuana. The most significant results are achieved when this form of treatment is combined with conventional types of anti-glaucoma treatment, although in a limited number of cases, THC therapy alone proved successful. Also disclosed is a dosage unit form for THC comprising a suitable dose of THC in combination with an innocuous diluent such as fructose.Other References
| |
